SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification

被引：3
|
作者：
Yu, Y. [1 ]
Yang, N. [2 ]
Zhang, Y. [3 ]
Zhang, H. [4 ]
Li, M. [5 ,16 ]
Yu, Q. [6 ]
Zhou, J. [7 ]
Hu, X. [8 ]
Fang, J. [9 ]
Zhao, H. [10 ]
Feng, J. [11 ]
Li, L. [12 ]
Shu, Y. [13 ]
Wang, X. [14 ]
Sun, M. [15 ]
Zhang, J. [15 ]
Li, M. [5 ,16 ]
Ren, Y. [15 ]
Lu, S. [1 ]
机构：
[1] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China
[2] Hunan Canc Hosp, Pulm Gastroenterol, Changsha, Peoples R China
[3] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Peoples R China
[4] Guangdong Prov Hosp Chinese Med, Dept Internal Med 1, Guangzhou, Peoples R China
[5] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[6] Guangxi Med Univ, Affiliated Tumor Hosp, Resp Oncol Dept, Nanning, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Resp Med Dept, Hangzhou, Peoples R China
[8] Henan Tumor Hosp, Med Oncol, Zhengzhou, Peoples R China
[9] Beijing Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[10] Anhui Med Univ, Hosp 2, Dept Pneumol, Hefei, Peoples R China
[11] Nantong Univ, Affiliated Hosp, Dept Resp & Crit Care Med, Nantong, Peoples R China
[12] Sichuan Univ, West China Hosp, Resp Dept, Lung Canc Ctr, Chengdu, Peoples R China
[13] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[14] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Peoples R China
[15] Haihe Biopharma Co Ltd, CSSD, Shanghai, Peoples R China
[16] Haihe Biopharma Co Ltd, BDS, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305MO
引用
下载
收藏
页码：S1553 / S1553
页数：1
相关论文
共 50 条
  • [21] TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI
    Ahn, M.
    Han, J.
    Sequist, L.
    Cho, B. C.
    Lee, J. S.
    Kim, S.
    Su, W.
    Tsai, C.
    Yang, J. C.
    Yu, H.
    Horn, L.
    Lee, K.
    Haddad, V.
    Frigault, M.
    Ahmed, G.
    Yang, L.
    Ghiorghiu, D.
    Oxnard, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1768 - S1768
  • [22] A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
    Song, Jiangdian
    Shi, Jingyun
    Dong, Di
    Fang, Mengjie
    Zhong, Wenzhao
    Wang, Kun
    Wu, Ning
    Huang, Yanqi
    Liu, Zhenyu
    Cheng, Yue
    Gan, Yuncui
    Zhou, Yongzhao
    Zhou, Ping
    Chen, Bojiang
    Liang, Changhong
    Liu, Zaiyi
    Li, Weimin
    Tian, Jie
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 3583 - 3592
  • [23] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
    Smit, E. F.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
  • [24] TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
    Han, J-Y.
    Sequist, L. V.
    Ahn, M-J.
    Cho, B. C.
    Yu, H.
    Kim, S-W.
    Yang, J. C-H.
    Lee, J. S.
    Su, W-C.
    Kowalski, D.
    Orlov, S.
    Cantarini, M.
    Verheijen, R. B.
    Mellemgaard, A.
    Frewer, P.
    Ou, X.
    Oxnard, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [26] INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
    Yang, J. C-H.
    Ellers-Lenz, B.
    Straub, J.
    Johne, A.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Phase II study of fruquintinib plus gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, Y.
    Su, W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Ahmad, A. R.
    Tho, L. M.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T-Y.
    Le, X.
    Eisert, A. K.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Lam, W-S.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    Van der Wekken, A. J.
    Hsia, T-C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1584
  • [29] Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
    Lam, Wei-Sen
    Le, Xiuning
    Eisert, Anna
    Himpe, Ulrike
    De Bondt, Charlotte
    Mazieres, Julien
    Petrini, Iacopo
    Tho, Lye Mun
    Ahmad, Azura
    Chik, Yin Kwan Jeannie
    Chung, Wai
    Lee, Kirsty
    Yang, Tsung-Ying
    Hsia, Te-Chun
    Joshi, Kirti
    Young, Louise
    Berghoff, Karin
    Vlassak, Soetkin
    Karachaliou, Niki
    van der Wekken, Anthonie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 83 - 84
  • [30] Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
    Le, X.
    Eisert, A.
    Himpe, U.
    De Bondt, C.
    Mazieres, J.
    Petrini, I.
    Tho, L. M.
    Ahmad, A.
    Lam, W. -S.
    Chik, Y. K. J.
    Lee, W. C. K.
    Yang, T. -Y.
    Joshi, K.
    Berghoff, K.
    Vlassak, S.
    Karachaliou, N.
    v. d. Wekken, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S483 - S484
12345